ECSP19026563A - Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos - Google Patents

Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos

Info

Publication number
ECSP19026563A
ECSP19026563A ECSENADI201926563A ECDI201926563A ECSP19026563A EC SP19026563 A ECSP19026563 A EC SP19026563A EC SENADI201926563 A ECSENADI201926563 A EC SENADI201926563A EC DI201926563 A ECDI201926563 A EC DI201926563A EC SP19026563 A ECSP19026563 A EC SP19026563A
Authority
EC
Ecuador
Prior art keywords
compounds
pyrimidin
amine
pyrazole
prophylaxis
Prior art date
Application number
ECSENADI201926563A
Other languages
English (en)
Inventor
Thomas Müller
David Engel
Andre Philippe Dieskau
Anna Lena Andreevski
Antje Kahnert
Jan Dreher
Karl Collins
Alexander Ehrmann
Jürgen Klar
Niels Lindner
Carsten Schmeck
Jens Willwacher
Anja Giese
Alexey Gromov
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of ECSP19026563A publication Critical patent/ECSP19026563A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos sustituidos de 6-(1H-pirazol-1-il)pirimidin-4-amina de la fórmula general (I) tal como se describen y definen en el presente, procedimientos para preparar dichos compuestos, compuestos de productos intermedios útiles para preparar dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos, y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular para el tratamiento y/o profilaxis de enfermedades cardiovasculares y renales ,como agente único o en combinación con otros compuestos activos.
ECSENADI201926563A 2016-10-14 2019-04-12 Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos ECSP19026563A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16193953 2016-10-14

Publications (1)

Publication Number Publication Date
ECSP19026563A true ECSP19026563A (es) 2019-04-30

Family

ID=57136772

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201926563A ECSP19026563A (es) 2016-10-14 2019-04-12 Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos

Country Status (28)

Country Link
US (2) US11208400B2 (es)
EP (1) EP3526212B1 (es)
JP (1) JP2019532961A (es)
KR (1) KR20190065402A (es)
CN (1) CN110191884A (es)
AR (1) AR109947A1 (es)
AU (1) AU2017341324A1 (es)
BR (1) BR112019007496A2 (es)
CA (1) CA3040166A1 (es)
CL (1) CL2019001004A1 (es)
CO (1) CO2019003761A2 (es)
CR (1) CR20190192A (es)
CU (1) CU24518B1 (es)
DO (1) DOP2019000099A (es)
EA (1) EA201990947A1 (es)
EC (1) ECSP19026563A (es)
GE (2) GEAP202115076A (es)
IL (1) IL265923A (es)
JO (1) JOP20190080A1 (es)
MA (1) MA46514A (es)
MX (1) MX381873B (es)
PE (1) PE20191549A1 (es)
PH (1) PH12019500808A1 (es)
SG (1) SG11201903305XA (es)
TN (1) TN2019000114A1 (es)
TW (1) TW201825477A (es)
UY (1) UY37444A (es)
WO (1) WO2018069222A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110734428A (zh) * 2019-10-24 2020-01-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN115403524A (zh) * 2021-05-26 2022-11-29 浙江省化工研究院有限公司 3-氟代吡唑羧酸酯、3-氟代烷基-1-取代吡唑-4-羧酸的制备方法
CN119894870A (zh) 2022-09-19 2025-04-25 巴斯夫欧洲公司 唑杀有害生物化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
HK1041703A1 (zh) 1999-01-21 2002-07-19 Board Of Regents The University Of Texas System 肠道顶膜钠/磷酸盐共同传送的抑制剂
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CA2684240A1 (en) * 2007-04-16 2008-10-30 Serenex, Inc. Tetrahydroindole and tetrahydroindazole derivatives
JP2008296610A (ja) 2007-05-29 2008-12-11 Toyota Motor Corp 車両用動力伝達装置の制御装置
JP5539963B2 (ja) * 2008-04-29 2014-07-02 ノバルティス アーゲー 線維芽細胞増殖因子受容体のキナーゼ活性のモジュレーションをモニタリングする方法、および該方法の使用
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AU2011219746B2 (en) 2010-02-27 2015-04-23 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA026692B1 (ru) * 2010-06-30 2017-05-31 Айронвуд Фармасьютикелз, Инк. Стимуляторы sgc
WO2012006475A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590656B1 (en) 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827328B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827326B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
PH12013500055A1 (en) 2010-07-09 2017-08-23 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AU2012329913A1 (en) 2011-10-27 2014-05-22 Astellas Pharma Inc. Aminoalkyl-substituted N-thienyl benzamide derivative
WO2013082756A1 (en) 2011-12-06 2013-06-13 Leo Pharma A/S Phosphate transport inhibitors ii
WO2014152716A1 (en) 2013-03-15 2014-09-25 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
TWI582083B (zh) * 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物
EA032137B1 (ru) 2014-11-03 2019-04-30 Байер Фарма Акциенгезельшафт Производные гидроксиалкил-замещенного фенилтриазола и их применение
CN105631664A (zh) 2014-11-26 2016-06-01 华为终端（东莞）有限公司 一种非接触支付方法、装置及系统
US10266517B2 (en) * 2014-12-23 2019-04-23 Dana-Farber Cancer Institute, Inc. Pyrimidines as EGFR inhibitors and methods of treating disorders
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
ES2949414T3 (es) 2016-10-14 2023-09-28 Novartis Ag Formas cristalinas de 4-(2-((1R,2R)-2-hidroxiciclohexilamino)benzotiazol-6-iloxi)-N-metilpicolinamida
ES2945822T3 (es) 2016-10-14 2023-07-07 Inst Pasteur De Montevideo Moduladores antinflamatorios y metabólicos pluripotentes para el tratamiento de afecciones relacionadas con la inflamación

Also Published As

Publication number Publication date
DOP2019000099A (es) 2019-07-15
US20200055842A1 (en) 2020-02-20
CN110191884A (zh) 2019-08-30
TN2019000114A1 (en) 2020-10-05
EA201990947A1 (ru) 2019-08-30
CU24518B1 (es) 2021-06-08
BR112019007496A2 (pt) 2019-09-10
PH12019500808A1 (en) 2020-01-20
CA3040166A1 (en) 2018-04-19
KR20190065402A (ko) 2019-06-11
TW201825477A (zh) 2018-07-16
UY37444A (es) 2018-05-31
IL265923A (en) 2019-06-30
EP3526212B1 (en) 2021-12-22
US20230065629A1 (en) 2023-03-02
AU2017341324A1 (en) 2019-05-02
CU20190035A7 (es) 2019-11-04
CL2019001004A1 (es) 2019-08-30
MX381873B (es) 2025-03-13
US11208400B2 (en) 2021-12-28
WO2018069222A1 (en) 2018-04-19
CO2019003761A2 (es) 2019-04-30
EP3526212A1 (en) 2019-08-21
MX2019004347A (es) 2019-07-01
JP2019532961A (ja) 2019-11-14
MA46514A (fr) 2019-08-21
GEAP202115076A (en) 2021-01-25
CR20190192A (es) 2019-09-02
PE20191549A1 (es) 2019-10-24
JOP20190080A1 (ar) 2019-04-11
AR109947A1 (es) 2019-02-06
SG11201903305XA (en) 2019-05-30
GEP20217269B (en) 2021-06-25

Similar Documents

Publication Publication Date Title
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2017002650A1 (es) Compuestos novedosos
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CU20170009A7 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CU20130033A7 (es) Imidazopiridazinas sustituidas
MX2014002697A (es) Imidazopiridazinas sustituidas con amino.
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
PE20151759A1 (es) Imidazopiridazinas sustituidas
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
NI201600006A (es) Pirazolo-piridinaminas sustituidas
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
UY35848A (es) Tienopirimidinas
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos
ECSP19026563A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
UY36983A (es) Pirazolopiridinaminas sustituidas
UY37032A (es) Compuestos de heteroarilbenzimidazol
UY34630A (es) Imidazopiridazinas sustituidas con amino